miR‑501‑3p sensitizes glioma cells to cisplatin by targeting MYCN

Zhang,Chuan‑Gang; Yang,Fan; Li,Yan‑Hua; Sun,Yan; Liu,Xue‑Jian; Wu,Xia

doi:10.3892/mmr.2018.9458

miR‑501‑3p sensitizes glioma cells to cisplatin by targeting MYCN

Authors:
- Chuan‑Gang Zhang
- Fan Yang
- Yan‑Hua Li
- Yan Sun
- Xue‑Jian Liu
- Xia Wu
View Affiliations

Affiliations: Department of Oncology, The Third People's Hospital of Linyi, Linyi, Shandong 276023, P.R. China, Department of Neurosurgery, The Third People's Hospital of Linyi, Linyi, Shandong 276023, P.R. China, Department of Teaching and Reach of Obstetrics and Gynecology, Shandong Medical College, Linyi, Shandong 276000, P.R. China
Published online on: September 5, 2018 https://doi.org/10.3892/mmr.2018.9458
Pages: 4747-4752

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin, a commonly used chemotherapeutic agent for glioma patients, treatment often leads to chemoresistance. Accumulating evidence has demosntrated that microRNA (miRNA/miR) is involved in drug resistance of glioma cells. Nevertheless, the role of miR‑501‑3p in glioma cell resistance to cisplatin is unclear. In the present study, it was revealed that miR‑501‑3p expression was decreased in glioma tissues and further underexpressed in cisplatin‑resistant glioma cells compared with wild‑type (WT) glioma cells. Furthermore, cisplatin treatment inhibited the level of miR‑501‑3p in a time‑dependent way. Ectopic expression of miR‑501‑3p suppressed glioma cell growth and invasion, but increased cisplatin‑resistant glioma cell apoptosis. Furthermore, miR‑501‑3p sensitized glioma cells to cisplatin‑induced proliferation arrest and death. Mechanistically, it was demonstrated that miR‑501‑3p targeted MYCN in glioma cells. In addition, it was revealed that miR‑501‑3p inhibited MYCN expression by a luciferase reporter assay and reverse transcription‑quantitative polymerase chain reaction. Notably, restoration of MYCN reversed the effects of miR‑501‑3p in cisplatin‑resistant glioma cells. In conclusion, these results suggested that miR‑501‑3p may serve a promising marker for cisplatin resistance.

View Figures

View References

1	Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han S, Peng B, Liu W and He X: miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int J Oncol. 47:1603–1611. 2015. View Article : Google Scholar : PubMed/NCBI
2	Han L, Liu D, Li Z, Tian N, Han Z, Wang G, Fu Y, Guo Z, Zhu Z, Du C and Tian Y: HOXB1 is a tumor suppressor gene regulated by miR-3175 in glioma. PLoS One. 10:e01423872015. View Article : Google Scholar : PubMed/NCBI
3	Bageritz J, Puccio L, Piro RM, Hovestadt V, Phillips E, Pankert T, Lohr J, Herold-Mende C, Lichter P and Goidts V: Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell Death Differ. 21:929–940. 2014. View Article : Google Scholar : PubMed/NCBI
4	Yuan L, Yuan P, Yuan H, Wang Z, Run Z, Chen G, Zhao P and Xu B: miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1. Am J Cancer Res. 7:159–172. 2017.PubMed/NCBI
5	Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
6	Fujii T, Shimada K, Tatsumi Y, Hatakeyama K, Obayashi C, Fujimoto K and Konishi N: microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer. 15:8182015. View Article : Google Scholar : PubMed/NCBI
7	Hata A and Lieberman J: Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 8:re3. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB and Xu SS: Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 112:1241–1246. 2015. View Article : Google Scholar : PubMed/NCBI
9	Wang GB, Liu JH, Hu J and Xue K: miR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. Eur Rev Med Pharmacol Sci. 21:5065–5071. 2017.PubMed/NCBI
10	Zhi T, Yu T, Pan M, Nie E, Wu W, Wang X, Liu N, You Y, Wang Y and Zhang J: EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma. Oncotarget. 8:96239–96248. 2017. View Article : Google Scholar : PubMed/NCBI
11	Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu Q, Cao K and Li Q: miR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014. View Article : Google Scholar : PubMed/NCBI
12	Guo Y, Yan K, Fang J, Qu Q, Zhou M and Chen F: Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res. 32:412013. View Article : Google Scholar : PubMed/NCBI
13	Luo C, Yin D, Zhan H, Borjigin U, Li C, Zhou Z, Hu Z, Wang P, Sun Q, Fan J, et al: microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. Cell Death Dis. 9:5352018. View Article : Google Scholar : PubMed/NCBI
14	Sanches JGP, Xu Y, Yabasin IB, Li M, Lu Y, Xiu X, Wang L, Mao L, Shen J, Wang B, et al: miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD. Chem Biol Interact. 285:85–95. 2018. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Huang BS, Luo QZ, Han Y, Huang D, Tang QP and Wu LX: miR-223/PAX6 axis regulates glioblastoma stem cell proliferation and the chemo resistance to TMZ via regulating PI3K/Akt pathway. J Cell Biochem. 118:3452–3461. 2017. View Article : Google Scholar : PubMed/NCBI
17	Tian T, Mingyi M, Qiu X and Qiu Y: MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Oncotarget. 7:79584–79595. 2016. View Article : Google Scholar : PubMed/NCBI
18	Xiao S, Yang Z, Qiu X, Lv R, Liu J, Wu M, Liao Y and Liu Q: miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. Oncotarget. 7:50229–50238. 2016. View Article : Google Scholar : PubMed/NCBI
19	Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, Wang X, Liu Y, Xu N, Yan X and Guo H: miR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 6:8914–8928. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yang Y, Wu J, Guan H, Cai J, Fang L, Li J and Li M: miR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
21	Qin XY, Suzuki H, Honda M, Okada H, Kaneko S, Inoue I, Ebisui E, Hashimoto K, Carninci P, Kanki K, et al: Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci USA. 115:4969–4974. 2018. View Article : Google Scholar : PubMed/NCBI
22	Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, et al: Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer. Clin Cancer Res. 24:696–707. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J and Wang R: MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 9:2202018. View Article : Google Scholar : PubMed/NCBI
24	Estiar MA, Javan F, Zekri A, Mehrazin M and Mehdipour P: Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma. Cancer Biomark. 19:341–351. 2017. View Article : Google Scholar : PubMed/NCBI
25	Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, et al: Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3:512–519. 2013. View Article : Google Scholar : PubMed/NCBI